ID
12147
Description
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072
Keywords
Versions (2)
- 9/30/15 9/30/15 -
- 10/28/15 10/28/15 -
Uploaded on
September 30, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
CLL Hospitalization NCT00090051 BO17072
MRU-Hospitalization of Chronic lymphocytic leukemia NCT0090051
- StudyEvent: ODM
Similar models
MRU-Hospitalization of Chronic lymphocytic leukemia NCT0090051
- StudyEvent: ODM
C0019993 (UMLS CUI [1,2])